A Clinical Study of KW-3357 in Patients Diagnosed as Disseminated Intravascular Coagulation (DIC) by the Diagnostic Criteria for DIC Established by the Japanese Ministry of Health and Welfare.

Trial Profile

A Clinical Study of KW-3357 in Patients Diagnosed as Disseminated Intravascular Coagulation (DIC) by the Diagnostic Criteria for DIC Established by the Japanese Ministry of Health and Welfare.

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Mar 2017

At a glance

  • Drugs Antithrombin gamma (Primary)
  • Indications Disseminated intravascular coagulation
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Kyowa Hakko Kirin
  • Most Recent Events

    • 03 Jul 2015 According to Kyowa Hakko Kirin media release, KW 3357 (ACOALAN) has been approved by the Misnistry of Health, Labour and Welfare of Japan.
    • 01 Aug 2014 Kyowa Hakko Kirin has submitted an application for approval in Japan for KW 3357, based on results from this trial and two other phase III trials, according to a Kyowa Hakko Kirin media release.
    • 01 Apr 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top